Client News

[Business Wire] - Aurinia Pharmaceuticals, Inc., today announced that its President and Chief Executive Officer Stephen Zaruby will present a corporate overview of the company at the BIO CEO Investor Conference, taking place February 9th-10th in New York at the Waldorf-Astoria Hotel.
Posted: January 29, 2015, 11:29 pm
[AP] - A look at the 10 biggest percentage decliners on Nasdaq at the close of trading: Ohr Pharmaceutical fell 32.1 percent to $7.74. Web.com Inc. fell 19.9 percent to $27.70. Aemetis Inc. fell 12.5 percent ...
Posted: January 29, 2015, 11:14 pm
Posted: January 29, 2015, 11:14 pm
[AP] - A look at the 10 biggest percentage gainers on Nasdaq at the close of trading: Tonix Pharma rose 26.5 percent to $7.40. Trillium Therapeutic rose 16.4 percent to $11.12. Ebix Inc. rose 14.3 percent to ...
Posted: January 29, 2015, 11:14 pm
[at noodls] - TEL AVIV, Israel, Jan. 29, 2015 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, ...
Posted: January 29, 2015, 1:21 pm
[GlobeNewswire] - TEL AVIV, Israel -- Alcobra Ltd. , an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity ...
Posted: January 29, 2015, 1:11 pm
[Business Wire] - Navidea Biopharmaceuticals, Inc. today announced that an analysis comparing sentinel lymph node biopsy procedures using Lymphoseek® injection + vital blue dye to filtered [99mTc] sulfur colloid + VBD in breast cancer patients was published in the Annals of Surgical Oncology.
Posted: January 29, 2015, 12:30 pm
[PR Newswire] - TEL-AVIV, Israel, Jan. 28, 2015 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral medication for the treatment of liver diseases and cholesterol gallstones, announced today that it has entered into a Manufacturing Services Agreement with Perrigo API Ltd., a subsidiary of Perrigo Company plc (PRGO) ("Perrigo"), for the large-scale production of the active pharmaceutical ingredient ("API") of Galmed's product candidate, aramchol. The API produced pursuant to this agreement is expected to provide sufficient quantities of aramchol for Galmed's potential future Phase III clinical trials of aramchol for the treatment of Non-Alcoholic Steato-Hepatitis, or NASH. According to the terms of the agreement, Perrigo will provide manufacturing process optimization services for large-scale production of the aramchol API, manufacture the aramchol API pursuant to current good manufacturing processes, or cGMP, and perform additional development services regarding scale-up and manufacturing optimization for the aramchol API. The agreement also provides Perrigo with the option to manufacture commercial supplies of the aramchol API in the future.
Posted: January 28, 2015, 1:00 pm